Singapore-based Tessa Therapeutics, a Temasek-backed clinical stage biotech company, has been granted Regenerative Medicine Advanced Therapy (RMAT) designation for its experimental CD30-directed autologous Car-T cell candidate by the US Food and Drug Administration.
The designation relates to treatment of patients with relapsed or refractory CD30-positive classical Hodgkin lymphoma (cHL).
Tessa expects to initiate a pivotal Phase II multi-site trial in this indication in the fourth quarter of 2020.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze